{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:34:47Z","timestamp":1756384487406},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,8]]},"DOI":"10.7759\/cureus.12568","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T08:16:13Z","timestamp":1610093773000},"source":"Crossref","is-referenced-by-count":1,"title":["Olanzapine-Associated Rhabdomyolysis: A Case Report"],"prefix":"10.7759","author":[{"given":"Valentin Y","family":"Skryabin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Zastrozhin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry A","family":"Sychev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S209284","article-title":"A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future","volume":"15","author":"Citrome L","year":"2019","unstructured":"Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatr Dis Treat. 2019, 15:2559-2569. 10.2147\/NDT.S209284","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1701823","article-title":"New discoveries for an old drug: a review of recent olanzapine research","volume":"132","author":"Meftah AM","year":"2020","unstructured":"Meftah AM, Deckler E, Citrome L, Kantrowitz JT. New discoveries for an old drug: a review of recent olanzapine research. Postgrad Med. 2020, 132:80-90. 10.1080\/00325481.2019.1701823","journal-title":"Postgrad Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions","volume":"9","author":"Urichuk L","year":"2008","unstructured":"Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008, 9:410-418. 10.2174\/138920008784746373","journal-title":"Curr Drug Metab"},{"key":"ref4","article-title":"Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine","volume":"276","author":"Ring BJ","year":"1996","unstructured":"Ring BJ, Catlow J, Lindsay TJ, et al.. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther. 1996, 276:658-666.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.13.120","article-title":"Pharmacogenetics of olanzapine metabolism","volume":"14","author":"S\u00f6derberg MM","year":"2013","unstructured":"S\u00f6derberg MM, Dahl ML. Pharmacogenetics of olanzapine metabolism. Pharmacogenomics. 2013, 14:1319-1336. 10.2217\/pgs.13.120","journal-title":"Pharmacogenomics"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2010.02168.x","article-title":"Pharmacogenomics of antipsychotics efficacy for schizophrenia","volume":"65","author":"Cacabelos R","year":"2011","unstructured":"Cacabelos R, Hashimoto R, Takeda M. Pharmacogenomics of antipsychotics efficacy for schizophrenia. Psychiatry Clin Neurosci. 2011, 65:3-19. 10.1111\/j.1440-1819.2010.02168.x","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jramc-2018-000939","article-title":"Severe rhabdomyolysis induced by quetiapine and mirtazapine in a French military soldier","volume":"164","author":"Saguin E","year":"2018","unstructured":"Saguin E, Keou S, Ratnam C, Mennessier C, Delacour H, Lahutte B. Severe rhabdomyolysis induced by quetiapine and mirtazapine in a French military soldier. J R Army Med Corps. 2018, 164:127-129. 10.1136\/jramc-2018-000939","journal-title":"J R Army Med Corps"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10370","article-title":"Olanzapine-induced rhabdomyolysis","volume":"35","author":"Rosebraugh CJ","year":"2001","unstructured":"Rosebraugh CJ, Flockhart DA, Yasuda SU, Woosley RL. Olanzapine-induced rhabdomyolysis. Ann Pharmacother. 2001, 35:1020-1023. 10.1345\/aph.10370","journal-title":"Ann Pharmacother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2017.01.1410","article-title":"Isolated rhabdomyolysis caused by olanzapine: about a clinical case","volume":"41","author":"Laajili Y","year":"2017","unstructured":"Laajili Y, Ellini S, Rebhi H, Haloui N, Cheour M. Isolated rhabdomyolysis caused by olanzapine: about a clinical case. Eur Psychiatry. 2017, 41:755. 10.1016\/j.eurpsy.2017.01.1410","journal-title":"Eur Psychiatry"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1684\/abc.2018.1351","article-title":"Antipsychotic induced rhabdomyolysis","volume":"1","author":"Ratnam C","year":"2018","unstructured":"Ratnam C, Saguin E, Keou S, Plantamura J, Mennessier C, Lahutte B, Delacour H. Antipsychotic induced rhabdomyolysis. Ann Biol Clin (Paris). 2018 Jun, 1:329-335. 10.1684\/abc.2018.1351","journal-title":"Ann Biol Clin (Paris)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2016094","article-title":"Delayed-onset rhabdomyolysis related to olanzapine: a case report","volume":"57","author":"Lee YF","year":"2016","unstructured":"Lee YF, Mao WC, Tai YM, Chang HA, Kao YC. Huang SY, Tzeng NS. Delayed-onset rhabdomyolysis related to olanzapine: a case report. Singapore Med J. 2016, 57:279. 10.11622\/smedj.2016094","journal-title":"Singapore Med J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2020.101015","article-title":"Rhabdomyolysis","volume":"66","author":"Cabral BMI","year":"2020","unstructured":"Cabral BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Dis Mon. 2020, 66:101015. 10.1016\/j.disamonth.2020.101015","journal-title":"Dis Mon"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-019-0480-8","article-title":"Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe","volume":"28","author":"Petrovi\u0107 J","year":"2020","unstructured":"Petrovi\u0107 J, Pe\u0161i\u0107 V, Lauschke VM. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet. 2020, 28:88-94. 10.1038\/s41431-019-0480-8","journal-title":"Eur J Hum Genet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.33.s2.3.x","article-title":"Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication","volume":"33","author":"Cascorbi I","year":"2003","unstructured":"Cascorbi I. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur J Clin Invest. 2003, 33:17-22. 10.1046\/j.1365-2362.33.s2.3.x","journal-title":"Eur J Clin Invest"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S149069","article-title":"The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo","volume":"8","author":"Sychev DA","year":"2018","unstructured":"Sychev DA, Ashraf GM, Svistunov AA, et al.. The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo. Drug Des Devel Ther. 2018, 8:1147-1156. 10.2147\/DDDT.S149069","journal-title":"Drug Des Devel Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/01.SMJ.0000076461.67623.E4","article-title":"Antihistamine-induced rhabdomyolysis","volume":"96","author":"Khosla U","year":"2003","unstructured":"Khosla U, Ruel KS, Hunt DP. Antihistamine-induced rhabdomyolysis. South Med J. 2003, 96:1023-1026. 10.1097\/01.SMJ.0000076461.67623.E4","journal-title":"South Med J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000465","article-title":"Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?","volume":"150","author":"Meltzer HY","year":"2000","unstructured":"Meltzer HY. Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?. Psychopharmacology (Berl). 2000, 150:349-350. 10.1007\/s002130000465","journal-title":"Psychopharmacology (Berl)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2677","article-title":"Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers","volume":"33","author":"Zastrozhin MS","year":"2018","unstructured":"Zastrozhin MS, Sorokin AS, Agibalova TV, et al.. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. Hum Psychopharmacol. 2018, 33:2677. 10.1002\/hup.2677","journal-title":"Hum Psychopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.13.76","article-title":"The clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists","volume":"14","author":"Mills R","year":"2013","unstructured":"Mills R, Haga SB. The clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. Pharmacogenomics. 2013, 14:957-968. 10.2217\/pgs.13.76","journal-title":"Pharmacogenomics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/48439-olanzapine-associated-rhabdomyolysis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:18Z","timestamp":1707507138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/48439-olanzapine-associated-rhabdomyolysis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.12568","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,8]]}}}